Oricell Therapeutics Holdings Limited, a global leader in innovative cancer immunotherapy, announced the successful closing of a $70 million Series C1 financing round. The investment round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a top global healthcare fund. Additional participation came from NGS Super, E-Town Capital, Elikon Venture, and Talon Capital. The funds will support Oricell’s international expansion, accelerate clinical development, enhance its technological platforms, and pave the way toward commercialization of its therapies.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
Oricell is developing a differentiated pipeline of CAR-T cell therapies targeting solid tumors. The company relies on three proprietary platforms that have been refined over the past decade. The Ori®Ab platform focuses on antibody discovery and engineering. OriArmoring enhances T-cell persistence and other critical functions for therapeutic use. The OnGo (Fast) CMC platform enables rapid, scalable, and efficient manufacturing of CAR-T products. These integrated platforms have allowed Oricell to generate proof-of-concept clinical data for multiple pipeline products.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
The company’s lead candidate, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma. Both a Phase I Investigator-Initiated Trial and a Phase I IND study have been completed, demonstrating strong efficacy and safety results. Ori-C101 has been highlighted at major academic conferences including ASCO 2021 and ASCO 2025. The therapy is now preparing to enter a registrational pivotal trial and is on track to potentially become the first approved CAR-T treatment for hepatocellular carcinoma worldwide.
Beyond Ori-C101, Oricell is developing next-generation CAR-T therapies with multi-target and multi-mechanism designs. OriC902, a secreting CAR-T, has shown promising results in patients with late-line and difficult-to-treat solid tumors. The company has also launched an Investigator-Initiated Trial to test a proprietary dual-targeted in vivo CAR-T therapy, reflecting its commitment to innovation across multiple therapeutic approaches.
Dr. Helen Yang, Chairlady and CEO of Oricell Therapeutics, expressed gratitude for the investors’ confidence and emphasized the company’s mission to advance global clinical development of its pipeline. She explained that Oricell aims to accelerate research and development of in vivo therapies and other cutting-edge technologies while making effective and affordable cell therapies accessible to cancer patients worldwide. She highlighted that the company’s technical expertise, favorable policy environment, and growing market opportunities provide a strong foundation to achieve these goals.
Mr. Peng Ren, Chairman and General Manager of Beijing Medical and Health Care Industry Investment Fund, stated that cell therapy represents a critical frontier in treating solid tumors. He praised Oricell’s clinical progress with GPC3 CAR-T in hepatocellular carcinoma and emphasized confidence in the company’s research and commercial vision. Mr. Xubo Hu, Managing Partner of Qiming Venture Partners, remarked that Oricell has evolved from a promising startup into a global technology leader. He highlighted the company’s advancements in autologous and secreting CAR-T therapies, rapid manufacturing capabilities, and ongoing development of in vivo CAR-T approaches. He reiterated his support for Oricell’s mission to deliver innovative and impactful immunotherapies on a global scale.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
